Dneasy blood dna extraction kit

Manufactured by Qiagen

Sourced in Spain, United States

The DNeasy Blood DNA Extraction Kit is a laboratory product designed to extract and purify DNA from blood samples. It utilizes a spin-column based technology to efficiently isolate high-quality genomic DNA suitable for various downstream applications.

Automatically generated - may contain errors

Lab products found in correlation

Bigdye terminator v3.1 kit, by Thermo Fisher Scientific (1 mentions) Abi 3500, by Thermo Fisher Scientific (1 mentions) Mytaq mix, by Meridian Bioscience (1 mentions)

Close spelling variants of this product

DNeasy kit (1236 citations) DNA extraction kit (652 citations) DNeasy extraction kit (103 citations) DNeasy Blood Kit (78 citations) DNeasy Blood and Tissue DNA extraction kit (61 citations) DNeasy DNA extraction kit (57 citations) DNA blood kit (56 citations) Blood DNA extraction kit (35 citations) DNeasy Blood & Tissue DNA extraction kit (12 citations) DNeasy Blood Extraction Kit (9 citations)

6 protocols using dneasy blood dna extraction kit

Genetic Profiling of Juvenile Open Angle Glaucoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Subjects with juvenile open angle glaucoma (JOAG) were recruited from ophthalmology clinics. When possible, subjects underwent an ophthalmologic exam, which included visual acuity assessment, slit-lamp examination to evaluate the anterior segment, dilated fundus examination to document the structural changes of glaucoma, and gonioscopic examination to evaluate the angle structure.
JOAG was defined as: 1) Age of diagnosis between age 3 and 40; 2) IOP > 21 mmHg; 3) open anterior chamber angle on gonioscopy (grade 3 or 4 of modified Shaeffer classification); 4) characteristic optic disc damage and/or typical visual field loss; and 5) absence of secondary causes of glaucoma.
In total 14 probands were recruited and pedigree information and disease status were ascertained. Symptomatic and asymptomatic family members were invited to participate. A total of 161 subjects from the 14 unrelated families were enrolled in the study and 45 of those underwent whole exome sequencing (WES) (Supp. Table S1). The proband from Family G was initially referred with a diagnosis of JOAG but after further clinical evaluation was determined to be a case of ocular hypertension and aniridia. Genomic DNA was extracted from the blood samples (10cc from venipuncture) with the DNeasy Blood DNA extraction kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions.

Collantes E.R., Delfin MS J.r., Fan B., Torregosa J.M., Siguan-Bell C., de Guzman Florcruz N.V., Martinez J.M., Masna-Hidalgo B.J., Guzman V.P., Anotado-Flores J.F., Levina F.D., Hernandez S.R., Collantes A.A., Sibulo M.C., Rong S, & Wiggs J.L. (2021). EFEMP1 rare variants cause familial juvenile-onset open angle glaucoma. Human mutation, 43(2), 240-252.

+ Open protocol

+ Expand

Genomic DNA Extraction from Blood

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hamdi Y., Mighri N., Boujemaa M., Mejri N., Ben Nasr S., Ben Rekaya M., Messaoud O., Bouaziz H., Berrazega Y., Rachdi H., Jaidane O., Daoud N., Zribi A., Ayari J., El Benna H., Labidi S., Ben Hassouna J., Haddaoui A., Rahal K., Benna F., Mrad R., Ben Ahmed S., Boussen H., Boubaker S, & Abdelhak S. (2021). Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers. Frontiers in Oncology, 11, 674965.

+ Open protocol

+ Expand

Quantifying Serum Circulating Cell-Free Mitochondrial DNA

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Serum circulating cell-free mitochondrial DNA (ccf-mtDNA) was quantified by first isolating DNA from 100 µl of serum using Qiagen DNeasy blood DNA extraction kit (69504), according to manufacturer’s instructions. Duplexed Taqman (iTaq, Bio-Rad) amplification of the mitochondrially-encoded genes MT-ND1 and MT-ND4 is then undertaken using targeted probes as previously described.^{37 ,38 (link)}

Jennings M.J., Kagiava A., Vendredy L., Spaulding E.L., Stavrou M., Hathazi D., Grüneboom A., De Winter V., Gess B., Schara U., Pogoryelova O., Lochmüller H., Borchers C.H., Roos A., Burgess R.W., Timmerman V., Kleopa K.A, & Horvath R. (2022). NCAM1 and GDF15 are biomarkers of Charcot-Marie-Tooth disease in patients and mice. Brain, 145(11), 3999-4015.

+ Open protocol

+ Expand

Screening BRCA1/2 Mutations in Tunisian Participants

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Total genomic DNA was isolated from peripheral blood using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer’s instructions. DNA purity and concentration were measured using a NanoDrop^TM spectrophotometer.
Polymerase chain reaction reactions were performed on genomic DNA, following standard protocols. Sanger sequencing was performed using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA, United States) and a cycle sequencing reaction kit (Bigdye Terminator v3.1 kit, Applied Biosystems). Data was analyzed using BioEdit software version 7.2.5.
Sanger sequencing technique was first used to screen the c.211dupA mutation on exon 5 of BRCA1 (NM_007294.3) among all 122 participants. It was also used to validate the identified variants resulting from the NGS assays. Non-carriers of c.211dupA mutation were tested for other recurrent BRCA1/2 mutations in Tunisia namely BRCA1-c.798_799delTT, BRCA1-c.5266dupC, and BRCA2-c.1310_1313delAAGA (Mahfoudh et al., 2012 (link); Fourati et al., 2014 (link); Msolly and Kassab, 2015 ; Riahi et al., 2015 (link)).

Mighri N., Hamdi Y., Boujemaa M., Othman H., Ben Nasr S., El Benna H., Mejri N., Labidi S., Ayari J., Jaidene O., Bouaziz H., Ben Rekaya M., M’rad R., Haddaoui A., Rahal K., Boussen H., Boubaker S, & Abdelhak S. (2020). Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. Frontiers in Genetics, 11, 552971.

+ Open protocol

+ Expand

Molecular Detection of Trypanosoma evansi

Check if the same lab product or an alternative is used in the 5 most similar protocols

DNA was extracted from blood samples using the DNeasy^® blood DNA extraction kit (Qiagen, USA) following the manufacturer’s instructions; DNA was stored at −20°C until used. Forward (5’-CTC CTC GTG TGG TGC ATA TT-3’) and reverse (5’-GAA GCG TAC ACG AAA GAA GC-3’) primers for PCR amplification were designed based on T. evansi nucleotide sequence (accession number FJ416612) in the GenBank database using the primer3online program (http://bioinfo.ut.ee/primer3-0.4.0). PCR was carried out in a 25 μL reaction volume containing 12.5 μL of master mix (MyTaq™ Mix, Bioline), 5 μL DNA template, 1 μL (10 μmol/L) each of primer, and 5.5 μL ddH₂O. The PCR amplification was performed as follows: An initial hold at 94°C for 4 min, then 35 cycles of denaturation at 94°C for 30 s, annealing at 57°C for 30 s, extension at 72°C for 30 s, and a final hold at 72°C for 5 min. PCR products were subjected to electrophoretic separation on 1% agarose gel at 100 volts for 30 min, stained with the FluoroVue™ Nucleic Acid Gel Staining reagent (SMOBIO Technology Inc., Taiwan), and visualized on an ultraviolet transilluminator. The positive samples were sequenced at First Base, Malaysia.

Setiawan A., Nurcahyo W., Priyowidodo D., Budiati R.T, & Susanti D.S. (2021). Genetic and parasitological identification of Trypanosoma evansi infecting cattle in South Sulawesi, Indonesia. Veterinary World, 14(1), 113-119.

+ Open protocol

+ Expand

Familial Breast Cancer Genomics

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tunisian families from different geographic origins were selected based on the following selection criteria; (1) having at least 3 breast cancer cases in first or second degree relatives at any age, (2) 2 breast cancer cases with one of them diagnosed with BC before age 40, (3) isolated breast cancer cases diagnosed before age 36, (4) one case with triple negative breast cancer (TNBC) at an age ≤ 40 years, (5) one case and one ovarian case diagnosed at first or second degree relatives at any age, (6) at least 2 cases with breast or ovarian cancer (at any age) and at least one case with pancreas cancer or prostate cancer at first or second degree relatives.
For each participant, total genomic DNA was extracted and used as a template for exome sequencing using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer's instructions. DNA purity and concentration were measured using a NanoDrop™ spectrophotometer.
When possible, genomic DNA samples from other affected or unaffected family members were obtained for further validation. Written informed consent was obtained from all participants. The study was conducted according to the Declaration of Helsinki Principles. Ethical approval was obtained from the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/Hôpital A-M).

Hamdi Y., Boujemaa M., Mighri N., Mejri N., Jaidane O., Ben Nasr S., Bouaziz H., Hassouna J.B., Zribi A., Berrazaga Y., Rachdi H., Daoud N., El Benna H., Labidi S., Haddaoui A., Rahal K., Benna F., Boussen H., Abdelhak S, & Boubaker S. (2021). Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology. Frontiers in Genetics, 12, 674990.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!